The Malaysian Advanced Prostate Cancer Consensus Conference (MyAPCCC 2018) was held to discuss the generalisability of consensus from the Advanced Prostate Cancer Consensus Conference (APCCC 2017) in Malaysia, a middle-income country. Questions that are relevant to the local clinical setting were chosen for voting. Twenty-two local key opinion leaders from urology and oncology met for the voting session.
Most voting results from the MyAPCCC 2018 were consistent with the APCCC 2017 outcomes. No consensus was achieved for controversial topics with little level I evidence, such as management of oligometastatic diseases. No consensus was reached on using high-cost drugs in castration-naïve or castration-resistant metastatic prostate cancer in real-world settings. All panellists recommended using generic drugs when available. Detailed questions and voting results are available in the supplementary data.
The MyAPCCC 2018 voting results reflect the management of advanced prostate cancer in a middle-income country in a real-world setting. These results may serve as a guide for local clinical practices and highlight the financial challenges in modern healthcare. This article is protected by copyright. All rights reserved.
BJU international. 2019 May 11 [Epub ahead of print]
Marniza Saad, Adlinda Alip, Jasmine Lim, Matin Mellor Abdullah, Flora Li Tze Chong, Chong Beng Chua, Fuad Ismail, Rachael Kit-Tsan Khong, Chun Sen Lim, Chit Sin Loh, Rohan Malek, Khairul Asri Mohd Ghani, Ibtisam Md Noor, Noor Ashani Md Yusoff, Noor Azam Nasuha, Azad Razack, Hwoei Fen Soo Hoo, Murali Sundram, Hui Meng Tan, Muthukkumaran Thiagarajan, Guan Chou Teh, Pei Jye Voon, Teng Aik Ong
Department of Clinical Oncology, University of Malaya Medical Centre, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Subang Jaya Medical Centre, Subang Jaya, Selangor, Malaysia., Department of Radiotherapy and Oncology, Sabah Women and Children Hospital, Kota Kinabalu, Sabah, Malaysia., Gleneagles Intan Medical Centre, Kuala Lumpur, Malaysia., Department of Oncology and Radiotherapy, National University of Malaysia, Kuala Lumpur, Malaysia., Department of Oncology and Radiotherapy, Sultan Ismail Hospital, Johor Bahru, Malaysia., Department of Urology, Selayang Hospital, Selangor, Malaysia., Faculty of Medicine and Health Sciences, University Putra Malaysia, Selangor, Malaysia., Department of Oncology and Radiotherapy, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia., Department of Urology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia., Department of Surgery, Raja Perempuan Zainab II Hospital, Kota Bharu, Kelantan, Malaysia., Department of Oncology and Radiotherapy, Penang Hospital, Penang, Malaysia., Department of Urology, Sarawak General Hospital, Sarawak, Malaysia., Department of Radiotherapy, Sarawak General Hospital, Oncology & Palliative Care, Sarawak, Malaysia.